Skip to main content
. 2018 Apr 1;10(4):102. doi: 10.3390/cancers10040102

Figure 2.

Figure 2

Failure time according to (a) EBV and MSI status (log-rank chi-square 9.34); (b) PD-L1 expression in the whole series (relative risk 2.44, log-rank chi-square 6.21); (c) PD-L1 expression in MSI GCs (relative risk 2.15, log-rank chi-square 2.13); (d) PD-L1 expression in MSS/EBV GCs (relative risk 0.30, log-rank chi-square 0.58); (e) PD-L1 expression in EBV+ GCs (relative risk 1.31, log-rank chi-square 0.13 p = 0.71) (f) and PD-L1 expression and CD8+ TILs (log-rank chi-square 7.75).